NCT06739213View on ClinicalTrials.gov

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 13, 2028

Conditions
Recurrent or Progressive High Grade Meningioma
Interventions
DRUG

SYHA1813

The starting dose of SYHA1813 is 20mg QD

DRUG

Investigator's Choice Treatment

Investigator's Choice Treatment

All Listed Sponsors
lead

Shanghai Runshi Pharmaceutical Technology Co., Ltd

INDUSTRY